Here are five takeaways:
1. The results demonstrate a single administration of PREOB has positive effects on pain and osteoporosis blood markers.
2. The trial currently involves seven patients who don’t respond to anti-osteoporotic therapy.
3. The patients experienced more than 40 percent decreases in pain. In comparison, patients receiving anabolic agent teriparatide saw a 30 percent decrease in pain.
4. Researchers found a decrease of more than 25 percent of bone resorption markers in an early phase of the 12-month follow-up.
5. The preliminary results suggest a single administration of PREOB stimulates bone remodeling, with a favorable bone formation-to-resorption ratio.
More articles on devices:
SpineCraft shows 4 technologies at AANS/CNS Spine Summit
Carestream introduces cone beam CT system for orthopedic practitioners — 4 insights
Anika’s CINGAL receives CE Mark approval — 5 highlights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
